130 related articles for article (PubMed ID: 17653913)
1. Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer.
Kälkner KM; Ullén A; Wersäll P; Cohn-Cedermark G
Acta Oncol; 2007; 46(6):862-3. PubMed ID: 17653913
[No Abstract] [Full Text] [Related]
2. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Beer TM; Tangen CM; Nichols CR; Margolin KA; Dreicer R; Stephenson WT; Quinn DI; Raghavan D; Crawford ED
Cancer; 2006 Jun; 106(12):2624-9. PubMed ID: 16688776
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
4. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
Donelli A; Chiodino C; Panissidi T; Roncaglia R; Torelli G
Haematologica; 2000 Sep; 85(9):1002-3. PubMed ID: 10980650
[No Abstract] [Full Text] [Related]
5. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
Litzow MR; Lee S; Bennett JM; Dewald GW; Gallagher RE; Jain V; Paietta EM; Racevskis J; Rousey SR; Mazza JJ; Tallman MS
Haematologica; 2006 Aug; 91(8):1105-8. PubMed ID: 16870552
[TBL] [Abstract][Full Text] [Related]
6. Arsenic-induced APL differentiation in cerebrospinal fluid.
Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
[TBL] [Abstract][Full Text] [Related]
7. [Anti-hepatoma effect of arsenic trioxide on rat liver cancers induced by 2-acetamidofluorene].
Huang JF; Tan B; Wei Q; Zhang H; Ni RZ
Zhonghua Gan Zang Bing Za Zhi; 2005 Aug; 13(8):623-5. PubMed ID: 16093000
[No Abstract] [Full Text] [Related]
8. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
[No Abstract] [Full Text] [Related]
9. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
10. Arsenic trioxide: safety issues and their management.
Au WY; Kwong YL
Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
[TBL] [Abstract][Full Text] [Related]
11. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
[No Abstract] [Full Text] [Related]
12. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
13. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
14. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
15. Clinical trials referral resource. Clinical trials with arsenic trioxide.
Murgo AJ; McBee WL; Cheson BD
Oncology (Williston Park); 2000 Feb; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
[No Abstract] [Full Text] [Related]
16. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
Dalton WS
Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
[No Abstract] [Full Text] [Related]
17. [Advances in the study on antineoplastic action of realgar].
Pan B; Xu L; Yang X
Zhong Yao Cai; 2004 Mar; 27(3):226-9. PubMed ID: 15346589
[No Abstract] [Full Text] [Related]
18. Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
Ofran Y; Avivi I; Gesundheit B; Or R; Rowe JM; Zuckerman T
Am J Hematol; 2007 Apr; 82(4):332-3. PubMed ID: 17080434
[No Abstract] [Full Text] [Related]
19. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.
Nouri K; Ricotti CA; Bouzari N; Chen H; Ahn E; Bach A
J Drugs Dermatol; 2006 Feb; 5(2):182-5. PubMed ID: 16485889
[TBL] [Abstract][Full Text] [Related]
20. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
